| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
bioAffinity Technologies, Inc.$0.77
-0.01 (-1.49%)
F 9Pipeline Score MedTech · Commercial
Market Cap
7.57 M
EPS
-11.31
P/E Ratio
-0.15 $
Value Trade
201.81 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.35 M
R&D Expenses
349.71 K
Operating CF
-3.23 M
Total Assets
7.95 M
Total Liabilities
4.28 M
Equity
3.66 M
D/E Ratio
12,345
-18.75 %
Week
-41.13 %
1 Month
33.33 %
3 Month
14.71 %
6 Month
-99.38 %
5 Year
-99.38 %
All Time
Cash Data
Cash Position
3.10 M
Monthly Burn
1.08 M
Runway
0.9 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
260.12 K
52 Week Range
0.69 - 13.80
% held by Insiders
3.26 %
% held by Institutions
6.41 %
Enterprise Value
5.86 M
Total Shares
4.54 M
Short %
18.56 %
Float Shares
4.40 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for bioAffinity Technologies, Inc.
169Total events
8Upcoming
15Tier-1 (high impact)
2022 – 2029Coverage
Upcoming catalysts 8
TBD
T2Quarterly Update
Expansion into Mid-Atlantic region and Veterans Administration healthcare system
Event history 161
Jul 7, 2026
▲Quarterly UpdateCorporate
CyPath Lung Q2 2026 sales more than doubled year-over-year and increased >30% sequentially
Jun 22, 2026
▲Preclinical PoCPreclinical
Positive preclinical findings for proprietary gene silencing technology in squamous skin cancer cells
squamous skin cancersource ↗
Jun 16, 2026
▲Partnership / LicenseCorporate
bioAffinity Technologies, Philips, and 4DMedical announce program to advance veteran lung health screening
lung health screeningsource ↗
Jun 16, 2026
Jun 2026
◆Enrollment UpdateTrial
Enrollment of 30-50 patients for deep suction validation study
lung cancersource ↗
Jun 2026
May 27, 2026
▲Patent GrantedIP / Competition
Mexico patent allowance for CyPath Lung flow cytometry methods
lung cancersource ↗
May 8, 2026
Apr 16, 2026
◆Oral PresentationPresentation
CyPath Lung featured at Cleveland Clinic Advances in Early Lung Cancer Detection symposium; CMO participates in panel
lung cancersource ↗
Drug Pipeline Intelligence
F9
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 7%
Micro Cap (rank 849 of 912)
Percentile RankbioAffinity Technologies, Inc. has significant pipeline risk (9/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CyPath® Lung | lung cancer detection | — | 2026-03-25 | 92% sensitivity, 87% specificity and 88% accuracy | bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice Read More | |
CyPath® Lung | lung cancer detection | — | 2026-03-25 | 92% sensitivity, 87% specificity and 88% accuracy | bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice Read More | |
CyPath® Lung | lung cancer detection | — | 2026-03-25 | 92% sensitivity, 87% specificity and 88% accuracy | bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BIAF
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BIAF Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BIAFbioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
bioAffinity Technologies has reported that its quarterly sales of CyPath® Lung have doubled, reaching a new record. This significant increase reflects the company's ongoing commercial momentum and suggests a positive trend in market acceptance of their product. The growth in sales highlights the effectiveness of their strategic initiatives.
Read more →BIAFSee what’s happening at bioAffinity Technologies…
bioAffinity Technologies has reported significant growth in sales of its CyPath® Lung test, with a nearly 300% increase in April 2026 compared to the previous year. The company is collaborating with Philips to improve lung cancer screening for U.S. veterans. Additionally, bioAffinity is advancing its research on companion diagnostics for asthma and COPD, as well as developing topical treatments for common skin cancers.
Read more →BIAFbioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
bioAffinity Technologies has announced positive preclinical findings regarding its proprietary gene silencing technology. The results indicate that this technology selectively targets squamous skin cancer cells while leaving healthy cells unharmed. This advancement could represent a significant step forward in cancer treatment strategies.
Read more →BIAFWallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
WallachBeth Capital announced the successful closing of bioAffinity Technologies' public offering, raising $3.2 million. The offering included 4 million shares priced at $0.80 each, aimed at funding the development of noninvasive lung cancer detection tests. The closing is subject to standard conditions and follows SEC regulations.
Read more →BIAFbioAffinity Technologies Announces Closing of $3.2 Million Offering
bioAffinity Technologies has announced the successful closing of a $3.2 million offering. This financial move is expected to support the company's ongoing projects and initiatives. Further details on the use of proceeds or future plans were not disclosed in the announcement.
Read more →BIAFWallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering
WallachBeth Capital announced that bioAffinity Technologies has priced a public offering of securities to raise $3.2 million. The offering consists of 4 million shares priced at $0.80 each, with the closing expected on June 18, 2026. The company aims to enhance early-stage lung cancer detection through its innovative testing solutions.
Read more →BIAF▼ -12%on this newsshared move
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
bioAffinity Technologies has announced the pricing of a $3.2 million offering. The details surrounding the offering, including its purpose and expected impact, were not disclosed in the article. This announcement may indicate the company's efforts to raise capital for future projects or initiatives.
Read more →BIAF▼ -31%on this newsshared move
bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
bioAffinity Technologies has announced a new program aimed at improving lung health for U.S. veterans. The initiative involves collaboration with Philips and 4DMedical to explore innovative screening methods. This program highlights the importance of addressing lung health issues within the veteran community.
Read more →BIAFMultidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
bioAffinity Technologies announced a webinar hosted by the Society for Advanced Bronchoscopy to discuss the CyPath® Lung test's role in early-stage lung cancer detection. The panel includes experts who will share insights on how this noninvasive test aids in diagnosis and management. CyPath® Lung has shown promising results in clinical trials, supporting better patient outcomes.
Read more →BIAFbioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
bioAffinity Technologies announced the allowance of a patent in Mexico for its CyPath® Lung technology, which uses flow cytometry to detect lung cancer. This patent will protect methods involving specific antibodies and porphyrin TCPP for identifying cancer cells in sputum. The company emphasizes that this innovation strengthens its intellectual property portfolio and supports early-stage lung cancer diagnostics.
Read more →BIAFbioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath Lung Technology Strong intellectual property portfolio helps build shareholder value Pa
bioAffinity Technologies has received patent allowance in Mexico for its CyPath Lung technology, which utilizes flow cytometry for lung cancer detection. This patent bolsters the company's intellectual property portfolio and supports its strategy for international market penetration. CyPath Lung is designed as a noninvasive test that aids in evaluating high-risk patients with indeterminate pulmonary nodules, emphasizing its high accuracy and negative predictive value. The positive outcomes of this technology aim to enhance early lung cancer diagnostics while providing clinical decision support.
Read more →BIAFbioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
bioAffinity Technologies has reported record monthly sales for its CyPath® Lung unit in April 2026, indicating significant growth compared to the previous year. The company continues to focus on expanding its market presence and enhancing its product offerings. This growth reflects the increasing demand for innovative lung cancer diagnostic solutions.
Read more →BIAFbioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
bioAffinity Technologies has reported its first quarter results for 2026, highlighting the ongoing adoption and clinical usage of its CyPath® Lung product. The company is focused on expanding its market presence and enhancing the capabilities of its offerings. Specific financial details and growth metrics were not disclosed in the article.
Read more →BIAF▲ +20.4%on this news
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
bioAffinity Technologies has initiated a pilot study with Brooke Army Medical Center to evaluate its flow cytometry and AI-based diagnostic tests for asthma and COPD. The study aims to identify inflammatory biomarkers to enhance treatment precision. Approximately 40 participants will be enrolled to assess the effectiveness of these innovative diagnostic tools in managing respiratory diseases, particularly in military personnel.
Read more →BIAFNew Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
bioAffinity Technologies released a case study on its CyPath® Lung diagnostic test, which helped confirm that a suspicious pulmonary nodule was likely due to inflammation rather than cancer. The test, which showed 92% sensitivity and 87% specificity, allowed physicians to defer an unnecessary biopsy, showcasing its value in managing high-risk patients. This case emphasizes the importance of noninvasive diagnostics in lung cancer assessment.
Read more →BIAFbioAffinity Technologies’ CyPath® Lung to be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
bioAffinity Technologies will showcase its CyPath® Lung test at the Cleveland Clinic's 'Advances in Early Lung Cancer Detection' symposium on April 16, 2026. Chief Medical Officer Gordon Downie will discuss lung nodule management, emphasizing the test's role in early detection. The symposium aims to enhance lung cancer diagnostics and treatment approaches.
Read more →BIAFbioAffinity Technologies' CyPath Lung to be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16 Invitation-only conference focuses on the evolving landscape of lung cancer ris
bioAffinity Technologies will feature its CyPath Lung test at the Cleveland Clinic's 'Advances in Early Lung Cancer Detection' symposium on April 16, 2026. The test utilizes noninvasive methodologies to aid in the early detection of lung cancer, with a focus on fragile patients with indeterminate pulmonary nodules. Chief Medical Officer Dr. Gordon Downie will participate in discussions surrounding lung nodule management, highlighting the benefits of incorporating CyPath Lung into current diagnostic practices. This represents bioAffinity's seventh presentation at this annual event, emphasizing the growing importance of innovative diagnostics in managing lung cancer risk.
Read more →BIAFbioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
bioAffinity Technologies reported a 146% increase in unit sales of its CyPath® Lung diagnostic test in Q1 2026 compared to the previous year. This growth is attributed to rising physician adoption and the test's effectiveness in assessing lung cancer risk. The company anticipates continued expansion in a growing market for pulmonary nodule management. CyPath® Lung utilizes advanced technology to provide critical information for clinical decision-making.
Read more →BIAFbioAffinity Technologies' CyPath Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026 Noninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 bil
bioAffinity Technologies reported a remarkable 146% increase in unit sales of its CyPath Lung diagnostic in Q1 2026 compared to Q1 2025. This growth reflects a broader acceptance and integration of the test among physicians for lung cancer risk assessment and management. With an expanding target market projected to reach $3.58 billion, the company aims to enhance early lung cancer detection while addressing increasing clinical needs for noninvasive diagnostics.
Read more →BIAFbioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
bioAffinity Technologies announced a live virtual physician roundtable focusing on the integration of CyPath® Lung into pulmonary practice. The webinar aims to address the need for improved diagnosis of indeterminate pulmonary nodules, featuring leading pulmonologists who will share real-world case studies. The event is scheduled for April 8, 2026, and will provide insights into the clinical utility of CyPath® Lung.
Read more →BIAF▲ +43.5%on this news
New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedure
bioAffinity Technologies has released a case study highlighting the effectiveness of its noninvasive CyPath® Lung test for lung cancer detection. The test provided a 'Unlikely Malignancy' result for a high-risk patient, allowing for a non-invasive approach instead of a biopsy. Follow-up scans confirmed the benign nature of the nodules, showcasing the test's potential to reduce healthcare costs and patient anxiety.
Read more →BIAF▲ +43.5%on this newsshared move
New Case Study: bioAffinity Technologies' CyPath Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures CyPath Lung improves diagnostic clarity in patients with multiple lung nodules In this
bioAffinity Technologies published a case study on its noninvasive diagnostic test, CyPath Lung, which aids in detecting lung cancer in high-risk patients with multiple pulmonary nodules. The study highlighted a specific case where a 71-year-old patient avoided invasive procedures due to a low likelihood of malignancy indicated by the test results. CyPath Lung demonstrated high sensitivity, specificity, and accuracy, thereby enhancing diagnostic confidence and supporting better patient management. The findings aim to illustrate the potential of CyPath Lung in minimizing unnecessary medical interventions and associated costs.
Read more →BIAF▲ +98.1%on this news· ran to +127% by day 3shared move
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
bioAffinity Technologies reported significant growth in 2025, with a record 87% increase in revenue from its CyPath® Lung diagnostic test. The number of tests performed rose by 99%, driven by expanded physician engagement and successful marketing strategies. Despite a decrease in total revenue due to the discontinuation of unprofitable services, the company is positioned for growth in 2026 with strong momentum and a focus on lung cancer diagnostics.
Read more →BIAF▲ +12.3%on this news· ran to +100% by day 3shared move
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
bioAffinity Technologies has launched a large-scale longitudinal clinical study for its CyPath® Lung diagnostic test, aimed at early detection of lung cancer in high-risk patients. The study will involve 2,000 participants and assess the test's performance using sputum samples. Previous trials showed promising sensitivity and specificity rates, and the study aims to gather real-world data to support its clinical utility.
Read more →BIAF▲ +12.3%on this news· ran to +100% by day 3shared move
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath Lung Cancer Diagnostic Study to evaluate clinical performance of CyPath Lung for the early detection of
bioAffinity Technologies, Inc. has announced the initiation of a large-scale longitudinal clinical study aimed at evaluating the effectiveness of its noninvasive diagnostic test, CyPath Lung, for early-stage lung cancer detection. The study will involve 2,000 high-risk patients and is supported by major medical institutions including the Murtha Cancer Center. Past trials have shown promising results with high sensitivity and specificity. The objective is to establish CyPath Lung as part of the standard care for lung cancer screening and diagnosis.
Read more →BIAFSputum-Based Test May Identify Drug Targets in Asthma and COPD – Patient Care Online
Recent research presented at the AAAAI 2026 meeting highlights the use of sputum flow cytometry to identify drug targets for asthma and COPD. This noninvasive method could shift treatment from trial-and-error to precision medicine, potentially improving patient outcomes. The study emphasizes the importance of directly analyzing sputum to better understand patients' inflammatory states.
Read more →BIAF▼ -10.3%on this news
bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
bioAffinity Technologies presented promising findings on its diagnostic platform at the AAAAI 2026 annual meeting. The platform aims to identify antibody drug receptors in sputum, which could enhance personalized treatment for asthma and COPD patients. The technology leverages advanced flow cytometry and AI to improve disease monitoring and treatment efficacy.
Read more →BIAFbioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test
bioAffinity Technologies has announced a validation study with Brooke Army Medical Center to assess the utility of the CyPath® Lung test on sputum samples collected via deep suctioning. The study aims to enroll 30-50 patients and is expected to yield results by mid-2026. This initiative could broaden the test's application in early lung cancer detection, leveraging existing clinical practices.
Read more →BIAF▼ -5.6%on this news
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer
bioAffinity Technologies released a case study demonstrating the effectiveness of its CyPath® Lung test in managing a 79-year-old patient with a suspicious lung nodule. The noninvasive test helped avoid an unnecessary biopsy by indicating a low likelihood of malignancy. Follow-up scans confirmed the initial findings, supporting the test's high sensitivity and specificity.
Read more →BIAFNew Case Study Highlights Ability of bioAffinity Technologies' CyPath Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer CyPath Lung test supported recommendation for surveillance strategy, rather than
bioAffinity Technologies has released a new clinical case study demonstrating the efficacy of its CyPath Lung noninvasive diagnostic test for lung cancer. The case involved a 79-year-old patient with a suspicious lung nodule who was able to avoid invasive procedures thanks to the test's results. CyPath Lung exhibited high sensitivity and specificity, thus supporting a conservative management strategy that was validated through follow-up scans showing no malignancy. This underscores the test's role in improving patient care for those at risk of lung cancer.
Read more →BIAFClinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study
bioAffinity Technologies announced a clinical case study showcasing the effectiveness of its CyPath® Lung test in a high-risk patient with multiple pulmonary nodules. The test returned a negative result, indicating a low likelihood of malignancy, which helped guide the patient's ongoing surveillance. This case emphasizes the test's role in alleviating patient anxiety and supporting clinical decisions.
Read more →BIAF▲ +12.2%on this news
bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board
bioAffinity Technologies has appointed three prominent experts to its Medical and Scientific Advisory Board to enhance its strategic priorities. The new members, Drs. Ost, Sterman, and Ferguson, will guide the integration of the CyPath®Lung diagnostic test into standard care for lung cancer. This move aims to improve early detection and treatment outcomes for patients with indeterminate pulmonary nodules.
Read more →BIAFbioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
bioAffinity Technologies has successfully retained its College of American Pathologists (CAP) accreditation for its Precision Pathology Laboratory Services. This accreditation underscores the laboratory's commitment to quality and patient safety. The company's CyPath® Lung test is positioned to address the growing need for early lung cancer diagnosis, with significant market potential projected by 2034.
Read more →BIAFbioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation CyPath Lung addresses urgent unmet need in projected $10.4 billion lung cancer diagnostic marke
bioAffinity Technologies has successfully maintained its CAP accreditation for its laboratory subsidiary, Precision Pathology Laboratory Services (PPLS), ensuring high standards of quality and safety. This accreditation highlights the reliability of the CyPath Lung test, which can detect lung cancer at early stages and addresses a significant unmet need in the expanding lung cancer diagnostic market, projected to reach $10.4 billion by 2034. The company's leadership emphasized the commitment to excellence in laboratory medicine and the growing demand for their diagnostic services among physicians.
Read more →BIAF▲ +9.8%on this news· ran to +20% by day 1
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
bioAffinity Technologies announced that its noninvasive CyPath® Lung test will be featured at the American Cancer Society National Lung Cancer Roundtable. Chief Medical Officer Dr. Gordon Downie will present three cases demonstrating the test's effectiveness in identifying Stage 1A lung cancer in challenging presentations. The test's high sensitivity and specificity support its role in improving early lung cancer diagnosis.
Read more →BIAFbioAffinity Technologies Reports Third Quarter 2025 Financial Results
bioAffinity Technologies reported a strong financial performance for Q3 2025, with an 86% increase in CyPath® Lung testing revenue driven by higher test volumes and clinical adoption, particularly within the Veterans Administration. Despite a decrease in total revenues due to the discontinuation of unprofitable services, the company raised $10.4 million to support growth initiatives. The introduction of new board members and expansion of their patent portfolio further strengthens their market position.
Read more →BIAFbioAffinity Technologies Reports Third Quarter 2025 Financial Results Company achieves 86% increase in CyPath Lung testing revenue, strengthens balance sheet
bioAffinity Technologies, Inc. reported its financial results for Q3 2025, revealing an 86% year-over-year increase in revenue from its CyPath Lung testing. This growth was attributed to higher test volumes and expanding market adoption, particularly among Veterans Administration hospitals. Despite a decline in total revenues, the company successfully raised $10.4 million to fund ongoing operations. The financial report also highlighted an increase in net loss due to expenses related to warrant valuations, amidst a strategic focus on their flagship product, CyPath Lung.
Read more →BIAFbioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
bioAffinity Technologies reported a 111% increase in the volume of its CyPath® Lung tests in October compared to the 2025 monthly average. The company noted consistent growth throughout the year, with a 95% increase in third-quarter sales. The test's efficacy in early lung cancer detection is gaining recognition among healthcare professionals, contributing to its adoption in clinical settings.
Read more →BIAFbioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath Lung Test Volume October test volume 111% more than 2025 year-to-date monthly average
bioAffinity Technologies reported a significant growth in the volume of its CyPath Lung test, with October's numbers soaring 111% above the 2025 monthly average. The company’s continued sales growth indicates a strong acceptance of their noninvasive lung cancer diagnostic by healthcare professionals. The test’s detection capabilities, underpinned by advanced flow cytometry and AI, show promise in early-stage lung cancer diagnosis. The ongoing upward trend in test adoption reflects the company’s effective outreach efforts and the increasing recognition of the test's clinical value.
Read more →BIAFbioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
bioAffinity Technologies announced the acceptance of an Australian patent application for its platform aimed at assessing lung health and predicting multiple lung diseases. The patent covers methods utilizing flow cytometry and fluorescent probes to detect cellular changes in sputum samples. This development strengthens the company's intellectual property portfolio, complementing existing patents in various countries.
Read more →BIAFbioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases Australian patent strengthens global patent portfolio
bioAffinity Technologies, Inc. announced the acceptance of a patent application for a proprietary platform designed to detect and characterize multiple lung diseases. This patent further solidifies the company’s global patent portfolio, complementing existing protections in numerous countries. The platform leverages advanced flow cytometry and AI to analyze sputum samples, enhancing early diagnosis of lung cancer. The flagship product, CyPath Lung, already demonstrates high efficacy in identifying lung cancer in patients with small nodules.
Read more →BIAFbioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
bioAffinity Technologies will present research on its CyPath® Lung processing methods at CHEST 2025. The study demonstrates the effectiveness of sample collection and transport for early-stage lung cancer detection. The company's noninvasive test has shown high sensitivity and specificity, with results typically available within two days. This presentation aims to engage healthcare professionals on improving patient outcomes.
Read more →BIAFbioAffinity Technologies Presents Research Supporting CyPath Lung Processing Methods at CHEST 2025 Visit the CyPath Lung team at Booth #2242 October 19-22
bioAffinity Technologies, Inc. announced that it will present research at CHEST 2025, highlighting the efficacy of its noninvasive CyPath Lung test for detecting early-stage lung cancer. The study demonstrates the reliability of the company's sample collection and handling methods. CEO Maria Zannes emphasized the importance of the research, while CMO Gordon Downie noted that results are typically available within two days for physicians. CyPath Lung has shown promising clinical study results, suggesting it could improve patient outcomes significantly.
Read more →BIAF▲ +25.8%on this newsshared move
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
bioAffinity Technologies announced the allowance of a new patent for its AI-based diagnostic algorithm and flow cytometry platform for lung cancer detection. The patent covers a method that analyzes sputum samples to predict lung cancer risk. This advancement complements the company's existing patent portfolio and enhances the capabilities of its CyPath® Lung test, which aims to improve early-stage lung cancer diagnosis.
Read more →BIAF▲ +25.8%on this newsshared move
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer U.S. award protects AI-built platform and adds to growing internationa
bioAffinity Technologies has announced that the United States Patent and Trademark Office has granted a notification of allowance for a patent related to its AI-based diagnostic algorithm and test method for lung cancer. This patent supports the CyPath Lung test, which is designed for the early detection of lung cancer by analyzing sputum samples. The test is associated with high sensitivity and specificity, thereby potentially improving outcomes for patients. Furthermore, this addition enhances bioAffinity's international patent portfolio, with 18 patents awarded globally.
Read more →BIAF▼ -5.9%on this news· ran to +18% by day 1shared move
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
bioAffinity Technologies, Inc. announced that it has regained compliance with Nasdaq's continued listing requirements. This compliance ensures that its common stock and warrants will continue trading on the Nasdaq Capital Market. The company's President, Maria Zannes, expressed that this allows the company to focus on advancing its CyPath Lung test and other innovations in cancer diagnostics. However, the firm is under a one-year Mandatory Panel Monitor, and failure to comply again could jeopardize its Nasdaq listing.
Read more →BIAFbioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. has successfully closed a $1.8 million registered direct financing by selling 720,000 shares of common stock at $2.50 each. The funds will be utilized for working capital and to support the anticipated growth of its noninvasive lung cancer test, CyPath® Lung. The offering was conducted under Nasdaq rules and follows a previously filed registration statement.
Read more →BIAF▲ +24.5%on this newsshared move
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules SAN ANTONIO, Texas (
bioAffinity Technologies, Inc. has announced a registered direct financing of approximately $1.8 million through the sale of 720,000 shares of common stock at $2.50 per share. This transaction is expected to close on or about October 9, 2025, pending customary closing conditions. The proceeds will be used for working capital and to support the anticipated sales growth of their noninvasive lung cancer test, CyPath Lung. The offering is made under a previously filed SEC registration statement.
Read more →BIAFbioAffinity Technologies Reports Record Growth in CyPath Lung Test Volume for Third Quarter 2025
bioAffinity Technologies reported significant growth in its CyPath Lung diagnostic test sales for the third quarter of 2025, indicating a 95% increase compared to the previous quarter. This growth highlights increased adoption within Veterans' hospitals and improved performance metrics, including a 77% rise in new patients using the test. The test's high accuracy underlines its effectiveness in early lung cancer detection, and the company remains optimistic about future sales and integration into clinical practice.
Read more →BIAF▼ -38.6%on this news
bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
bioAffinity Technologies, Inc. announced the pricing of a public offering that aims to generate $4.8 million in gross proceeds. The offering includes 1,921,799 shares of common stock priced at $2.50 each or pre-funded warrants. This move is expected to support the company's focus on developing noninvasive tests for the early detection of cancer. The closing of the offering is anticipated shortly, pending customary conditions.
Read more →BIAF▲ +55.1%on this newsshared move
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
bioAffinity Technologies has released three new case studies demonstrating the clinical value of its noninvasive diagnostic test, CyPath® Lung. The studies highlight successful early detection of Stage 1A lung cancer and the avoidance of invasive procedures for patients. CyPath® Lung has shown high sensitivity and specificity, reinforcing its role in improving lung cancer diagnostics.
Read more →BIAFbioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on
bioAffinity Technologies, Inc. has announced a 1-for-30 reverse stock split of its common stock, effective from September 19, 2025. This decision, approved by stockholders, aims to ensure compliance with Nasdaq's minimum bid price requirement. Post-split, the company will have around 1,338,029 shares outstanding. Additionally, adjustments will be made to stock options and warrants resulting from the split.
Read more →BIAFCase Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
bioAffinity Technologies announced a successful case study of its CyPath® Lung diagnostic tool, which identified lung cancer in a patient with ground-glass nodules. This noninvasive test shifted the patient's care from prolonged watchful waiting to immediate treatment. The technology demonstrated high sensitivity and specificity, providing actionable results that can improve patient outcomes.
Read more →BIAFCase Study: CyPath Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules bioAffinity Technologies' noninvasive diagnostic shifted the course of care from watchful waiting for up
bioAffinity Technologies has released a case study demonstrating the efficacy of its CyPath Lung diagnostic tool in identifying lung cancer in a patient with ground-glass pulmonary nodules. The test provided a likely malignant result, shifting the patient's care from watchful waiting to immediate treatment. This case highlights the potential of CyPath Lung to improve early detection and treatment outcomes for lung cancer, addressing challenges posed by traditional diagnostic methods that often rely on prolonged observation. The test has shown high sensitivity and specificity in clinical studies for detecting malignancy in patients with small lung nodules.
Read more →BIAFU.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
bioAffinity Technologies' CyPath® Lung has been featured in U.S. Medicine for its potential to enhance lung cancer detection among veterans while reducing costs for the Department of Veterans Affairs. The test demonstrates high diagnostic performance and could lead to significant healthcare savings. Its integration into standard care may improve patient outcomes by streamlining the diagnostic process.
Read more →BIAFU.S. Medicine Magazine Spotlights CyPath Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA Noninvasive diagnostic can help federal medical system address veterans at higher risk f
U.S. Medicine has spotlighted bioAffinity Technologies' CyPath Lung, a noninvasive diagnostic tool designed to enhance lung cancer detection among veterans. The article underscores the potential of CyPath Lung to significantly reduce costs for the Department of Veterans Affairs while improving patient care. Research indicates that integrating this test into the standard of care could lead to savings of approximately $895 million for private insurers and $379 million for Medicare. Additionally, clinical studies show that CyPath Lung exhibits high diagnostic performance, facilitating earlier detection of lung cancer, particularly in at-risk populations.
Read more →BIAFNew Test Shows Promise for Improving Lung Cancer Detection, Reducing Costs for VA – US Medicine, the Voice of Federal Medicine
A new study highlights CyPath Lung, a diagnostic test that enhances the evaluation of indeterminate pulmonary nodules in veterans. This noninvasive test shows improved sensitivity and specificity compared to traditional LDCT scans, leading to fewer unnecessary procedures and significant cost savings. The test is now available nationwide through VA health systems, promising better outcomes for veterans at risk of lung cancer.
Read more →BIAF▲ +5.1%on this news
bioAffinity Technologies Appoints New Members to Board of Directors
bioAffinity Technologies has appointed Roberto Rios and Dr. John J. Oppenheimer to its Board of Directors, enhancing its leadership team. Rios brings extensive financial expertise, while Oppenheimer contributes significant clinical experience in lung health. Their appointments are expected to bolster the company's growth in lung cancer diagnostics and related therapeutic markets.
Read more →BIAF▲ +5.1%on this newsshared move
bioAffinity Technologies Appoints New Members to Board of Directors Financial and Clinical Leaders Provide Significant Expertise for the Company's Commercial Growth SAN ANTONIO, Texas (
bioAffinity Technologies has announced the appointment of Roberto Rios and Dr. John J. Oppenheimer to its Board of Directors, aiming to enhance commercial growth and financial stability. Rios brings extensive executive leadership experience in corporate finance, while Oppenheimer offers significant clinical expertise in lung health. The addition of these directors is expected to strengthen the company's position in developing noninvasive diagnostics for lung diseases, notably through its product CyPath Lung. Gary Rubin has stepped down from the board for personal reasons but will continue to support the company.
Read more →BIAFbioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
bioAffinity Technologies has successfully closed a private placement transaction, raising approximately $1.2 million in gross proceeds. The transaction involved the sale of Series B Convertible Preferred Stock and warrants for common stock. Additionally, an existing investor exercised warrants, leading to a reduction in exercise prices, which may attract further investment. The company's product, CyPath® Lung, demonstrates promising results in early-stage lung cancer detection.
Read more →BIAF▼ -8.9%on this newsshared move
bioAffinity Technologies Reports Second Quarter 2025 Results
bioAffinity Technologies reported a strong second quarter for 2025, with a 62% increase in CyPath® Lung revenues compared to the previous year. The company highlighted significant growth in testing and successful case studies demonstrating the effectiveness of their diagnostic tool. However, they also reported a net loss of $4.1 million, reflecting strategic shifts in their business model. The appointment of a new Chief Medical Officer and partnerships to enhance logistics capabilities were also noted as positive developments.
Read more →BIAF▼ -8.9%on this newsshared move
bioAffinity Technologies Reports Second Quarter 2025 Results CyPath Lung revenues up 62% year-over-year in first six months of 2025 SAN ANTONIO, Texas (
bioAffinity Technologies, Inc. announced its financial results for the second quarter of 2025, reporting a 62% increase in CyPath Lung revenues year-over-year. This growth reflects the successful implementation of their commercialization strategy and increasing clinical adoption of their lung cancer diagnostic. Despite a reported net loss of $4.1 million due to various factors, the company took significant steps toward market expansion and technological advancement, including partnerships and the appointment of a new Chief Medical Officer. The company also demonstrated a commitment to improving patient outcomes through innovative diagnostic capabilities in the lung cancer space.
Read more →BIAFbioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
bioAffinity Technologies reported a remarkable 72% increase in sales of its CyPath® Lung test in July, following record sales in June. The company anticipates a threefold increase in year-over-year revenues, driven by heightened clinician adoption and positive patient outcomes. The test's ability to detect early-stage lung cancer has garnered significant attention, enhancing trust in its diagnostic capabilities.
Read more →BIAFbioAffinity Technologies Reports Accelerating Growth in CyPath Lung Test Sales July Test Volume Surges 72% Over Prior Monthly Average
bioAffinity Technologies, Inc. reported a notable increase in the sales volume of its CyPath Lung test, with a 72% surge in July compared to the previous monthly average. This growth trend follows record sales in both June and July, indicating strong market interest and clinician adoption. The company aims to triple year-over-year revenues for CyPath Lung, bolstered by successful pilot marketing programs and positive clinical outcomes. The test's ability to detect early-stage lung cancer is seen as crucial for improving survival rates among high-risk patients.
Read more →BIAFbioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds SAN ANTONIO, Texas (
bioAffinity Technologies, Inc. has announced a private placement of approximately $1.2 million through the issuance of Series B Convertible Preferred Stock and associated warrants. These funds will support the company’s working capital and other corporate purposes. Additionally, the company will complete a warrant inducement transaction, including the exercise of existing warrants at lowered prices. Their CyPath Lung test has showcased high efficacy in detecting early-stage lung cancer, highlighting the company’s innovative approach in biotechnology.
Read more →BIAFCase Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging and Low-Risk Serum Test Results
bioAffinity Technologies reported a successful case study where its CyPath® Lung test identified Stage 1A lung cancer in a high-risk patient. Despite inconclusive imaging and low-risk serum test results, the test prompted timely surgical intervention. The patient, who had a history of heavy smoking, successfully underwent surgery and has since quit smoking.
Read more →BIAFCase Study: CyPath Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging and Low-Risk Serum Test Results bioAffinity Technologies' noninvasive sputum test catches rare cancer in time for curati
bioAffinity Technologies announced a case study where its CyPath Lung test successfully detected Stage 1A lung cancer in a high-risk patient with inconclusive imaging results. The test revealed malignancy despite earlier assessments suggesting a low likelihood of cancer. This early detection enabled timely surgical intervention, underscoring the test's potential to significantly improve breast cancer outcomes specifically for high-risk individuals. CyPath Lung's advanced technology showcases its high sensitivity and specificity in identifying early-stage lung cancer cases that might be missed by traditional methods.
Read more →BIAFCase Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
bioAffinity Technologies' CyPath® Lung has demonstrated its effectiveness in detecting a Stage 1A neuroendocrine tumor that was previously misdiagnosed as non-cancerous. Despite inconclusive results from multiple diagnostic tests, the CyPath® Lung test indicated a high probability of cancer, leading to successful surgical intervention. This case highlights the importance of CyPath® Lung in the diagnostic process for challenging cases.
Read more →BIAFCase Study: CyPath Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools bioAffinity Technologies' noninvasive sputum test flagged difficult-to-diagnose cancer at earliest Stage 1A
bioAffinity Technologies announced a successful case study where its CyPath Lung test detected a Stage 1A neuroendocrine tumor that traditional diagnostic methods failed to identify. Despite inconclusive PET scans and bronchoscopies indicating non-cancerous inflammation, CyPath Lung provided critical insight that led to the patient's surgical removal of the tumor. This case highlights the test's potential as a vital tool for diagnosing early-stage lung cancer and improves patient outcomes.
Read more →BIAF▼ -6%on this newsshared move
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
bioAffinity Technologies has received a new patent in Canada for its CyPath® Lung diagnostic test, which detects lung cancer through flow cytometry analysis of sputum. This patent enhances the company's intellectual property portfolio and supports its mission to improve early cancer detection. With lung cancer being a leading cause of cancer deaths in Canada, the CyPath® Lung test aims to provide timely diagnosis and improve patient outcomes.
Read more →BIAF▼ -6%on this newsshared move
Canada Awards New Patent to bioAffinity Technologies for CyPath Lung, Company's Noninvasive Lung Cancer Diagnostic New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths
bioAffinity Technologies, Inc. has been awarded a new patent for its noninvasive lung cancer diagnostic, CyPath Lung, by the Canadian Patent Office. This patent will help strengthen the company's international market presence, particularly in Canada where lung cancer remains a significant health challenge. CyPath Lung has shown promising clinical results with high sensitivity and accuracy in early-stage lung cancer detection. However, bioAffinity faces risks associated with marketing and regulatory acceptance in a competitive environment.
Read more →BIAFbioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
bioAffinity Technologies has announced the allowance of a patent in China for its CyPath® Lung diagnostic test, which predicts lung cancer likelihood using flow cytometry. This patent is significant given China's large smoking population and high lung cancer rates. The company aims to expand its market presence in China, a major healthcare market for lung cancer diagnostics.
Read more →BIAFbioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic Nearly one-third of world's smokers live in China, which has one of the highest rates of lung cancer
bioAffinity Technologies has received notification from the China National Intellectual Property Administration for the allowance of a patent related to its noninvasive lung cancer diagnostic method. This patent aims to enhance the company's strategy to expand its presence in the Chinese market, where lung cancer rates are notably high due to the large smoking population. The CyPath Lung test has shown strong clinical results, with high sensitivity and specificity in detecting early-stage lung cancer, which will potentially save lives in this underserved healthcare market.
Read more →BIAFCase Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
bioAffinity Technologies announced a case study demonstrating that its noninvasive test, CyPath® Lung, successfully identified Stage 1A lung cancer in a high-risk patient despite inconclusive imaging results. The test provided crucial data that led to timely surgical intervention, highlighting its value in clinical decision-making. CyPath® Lung shows high sensitivity and specificity, making it a promising tool for early cancer detection.
Read more →BIAF▲ +46.9%on this news
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
bioAffinity Technologies presented groundbreaking research on a potential cancer therapy at the 2025 RNA Therapeutics Conference. The study focuses on using small interfering RNAs (siRNAs) to target CD320 and LRP2 receptors, effectively killing cancer cells while sparing normal cells. This innovative approach could lead to new RNA-based treatments for various cancers, enhancing patient outcomes.
Read more →BIAF▲ +7.7%on this news· ran to +29% by day 3shared move
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
bioAffinity Technologies has received a patent grant from the China National Intellectual Property Administration for its siRNA-based cancer therapy targeting CD320 and LRP2 receptors. This patent strengthens the company's global intellectual property portfolio and supports its innovative approach to cancer treatment. The technology aims to selectively kill cancer cells while preserving normal cells, with potential applications in various cancer types.
Read more →BIAFbioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board
bioAffinity Technologies' President and CEO, Maria Zannes, has been appointed to the American Lung Association in Texas' Leadership Board. This role allows her to contribute to the mission of improving lung health and preventing lung disease. Zannes' experience in advancing noninvasive lung cancer tests will be valuable for the organization.
Read more →BIAF▲ +7.6%on this news
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung
bioAffinity Technologies has partnered with Cardinal Health's OptiFreight Logistics to enhance the logistics of its CyPath® Lung test, a noninvasive diagnostic for early-stage lung cancer. The collaboration aims to ensure reliable delivery of sputum samples, which is crucial for accurate testing. With a focus on improving performance and addressing shipping challenges, this partnership supports the growing demand for the test, especially in rural areas.
Read more →BIAF▲ +46.8%on this news
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
bioAffinity Technologies has announced the issuance of a new U.S. patent for a method that selectively kills cancer cells by targeting specific cell receptors. This innovative approach utilizes small interfering RNAs (siRNAs) to suppress CD320 and LRP2 proteins, demonstrating effectiveness in vitro. The company aims to develop a topical treatment for skin cancers, marking a significant advancement in its therapeutic pipeline.
Read more →BIAF▲ +29.8%on this news
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
bioAffinity Technologies has appointed Dr. Gordon Downie as Chief Medical Officer, bringing over 30 years of experience in pulmonary medicine and clinical research. Dr. Downie emphasizes the importance of noninvasive diagnostics for lung cancer, particularly through the company's CyPath® Lung technology. His leadership is expected to enhance the company's clinical strategy and expand its diagnostic capabilities.
Read more →BIAF▼ -8.6%on this news· ran to +30% by day 3shared move
bioAffinity Technologies Reports First Quarter 2025 Results
bioAffinity Technologies reported a strong first quarter for 2025, with CyPath Lung sales increasing by 276% year-over-year, generating $1.9 million in revenue. The company implemented strategic actions to reduce costs by approximately $3.8 million while enhancing the efficiency of its diagnostic tests. Despite a net loss of $2.7 million, management remains optimistic about the growth potential of CyPath Lung and its commitment to expanding access to noninvasive lung cancer diagnostics.
Read more →BIAF▼ -8.6%on this news· ran to +30% by day 3shared move
bioAffinity Technologies Reports First Quarter 2025 Results CyPath Lung sales up 276% year-over-year SAN ANTONIO, Texas (
bioAffinity Technologies, Inc. reported significant financial outcomes for the first quarter of 2025, including a 276% increase in CyPath Lung sales compared to the previous year. The company generated $1.9 million in revenue, attributed mainly to patient service fees and histology services. In addition to strong sales growth, the company announced strategic actions aimed at reducing costs by $3.8 million annually while improving sales focus on high-margin diagnostics. Despite these positive developments, the company also reported a net loss of $2.7 million and a significant decrease in cash reserves.
Read more →BIAF▼ -5.3%on this news
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer
bioAffinity Technologies has released a white paper by Dr. Gordon Downie detailing the real-world impact of its CyPath® Lung test in diagnosing early-stage lung cancer. The paper showcases four clinical cases where the test improved diagnostic confidence and guided treatment decisions for high-risk patients. CyPath® Lung is noted for its high sensitivity and specificity in identifying malignancies in small pulmonary nodules.
Read more →BIAFbioAffinity Technologies Announces Closing of $3.25 Million Offering
bioAffinity Technologies has successfully closed a $3.25 million offering, providing funding for its noninvasive cancer detection technology. The offering included 10,156,250 shares of common stock and warrants for additional shares. The company's CyPath® Lung test has demonstrated high sensitivity and accuracy in detecting early-stage lung cancer, enhancing patient outcomes.
Read more →BIAF▼ -44.5%on this newsshared move
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
bioAffinity Technologies has announced the pricing of a $3.25 million offering, which includes 10,156,250 shares of common stock and warrants for additional shares. The offering is set to close on or about May 7, 2025, pending customary conditions. The funds raised will support the company's focus on noninvasive cancer detection technologies, particularly through its CyPath® Lung product.
Read more →BIAF▼ -44.5%on this newsshared move
bioAffinity Technologies Announces Pricing of $3.25 Million Offering SAN ANTONIO, Texas (
bioAffinity Technologies, Inc. has announced the pricing of a $3.25 million public offering, which includes shares of Common Stock and accompanying warrants. The offering aims to support the company’s development of noninvasive tests for detecting early-stage cancer, including their product CyPath Lung, which has demonstrated significant sensitivity and specificity in clinical studies. The offering is expected to close on or about May 7, 2025, pending customary conditions. This move positions bioAffinity Technologies for further advancement in the early cancer diagnosis market.
Read more →BIAF▲ +9.7%on this news
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
bioAffinity Technologies has announced enhancements to its CyPath® Lung test, improving data acquisition speed by nearly 50% and reducing processing costs by approximately 60%. These operational optimizations aim to increase overall throughput by more than 10% while maintaining high test performance. The changes are expected to provide significant economic benefits for both patients and healthcare systems.
Read more →BIAFbioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
bioAffinity Technologies reported a record revenue of $9.4 million for 2024, driven by a significant increase in demand for its CyPath® Lung test and expanded insurance coverage. The company also noted a substantial growth in its physician network and received recognition for its innovative diagnostic methods. However, it anticipates a revenue decline in 2025 due to the discontinuation of certain unprofitable services.
Read more →BIAFbioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 Increased Demand, Expanded Insurance Coverage Drive Record Growth SAN ANTONIO, Texas (
bioAffinity Technologies reported a record revenue of $9.4 million for 2024, representing a 270% increase from the previous year. The growth is attributed to a significant rise in demand for the CyPath Lung test, alongside expanded insurance coverage. In 2024, orders for CyPath Lung surged by approximately 1,400%, and the test was added to the Medicare reimbursement schedule. Despite these successes, the company anticipates a reduction in total revenue for 2025 due to the discontinuation of unprofitable services and reported a net loss of $9.0 million for 2024.
Read more →BIAFCase Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
bioAffinity Technologies announced a case study demonstrating the effectiveness of CyPath® Lung in detecting a second primary lung cancer in a patient with a history of lung cancer. The test provided critical real-time information that led to timely diagnosis and treatment. The study highlights the potential for CyPath® Lung to improve patient outcomes and reduce healthcare costs.
Read more →BIAF▲ +6.1%on this news
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
bioAffinity Technologies announced a case study demonstrating the effectiveness of CyPath® Lung in detecting a hidden recurrence of breast cancer in a high-risk patient. The technology's real-time assessment capabilities not only aid in lung cancer diagnostics but also enhance overall oncological decision-making. The study highlights significant cost savings and improved patient outcomes associated with its use.
Read more →BIAFbioAffinity Technologies Preps for Clinical Trial, Narrows Focus on its Lung Cancer Test
BioAffinity Technologies is set to begin a clinical trial for its CyPath Lung test, aimed at early lung cancer detection. The trial will recruit over 3,200 patients and support FDA marketing clearance. Despite facing potential Nasdaq delisting and financial losses, the company is focusing on expanding its operations and has recently cut costs significantly. The test has demonstrated promising sensitivity and specificity in initial studies.
Read more →BIAFPhysicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
bioAffinity Technologies, Inc. has released case studies highlighting the benefits of CyPath® Lung, a noninvasive test for early lung cancer detection. The test has successfully prevented unnecessary invasive procedures in high-risk patients, leading to improved patient outcomes. Additionally, economic evaluations suggest significant cost savings for healthcare systems when incorporating CyPath® Lung into standard care protocols.
Read more →BIAFSA Biotech Plans Big Cuts to Grow Core Company
BioAffinity Technologies Inc. is implementing significant operational changes to enhance financial performance and focus on its core product, CyPath Lung. The company plans to cut $4 million in operating costs, primarily through its subsidiary, while also expanding sales efforts in high-potential markets. Despite workforce reductions, these strategic adjustments aim to improve overall profitability and market readiness for noninvasive cancer detection.
Read more →BIAFbioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
bioAffinity Technologies has announced strategic measures to cut $4 million in costs while focusing on enhancing the sales growth of its CyPath® Lung test. This includes a significant workforce reduction at its subsidiary and operational efficiency improvements. The company aims to expand its market presence and improve profitability despite a potential decrease in revenue. Upcoming plans include launching a government marketing program for the test.
Read more →BIAFbioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath Lung Sales Growth Proactive steps reinforce bioAffinity Technologies' laser focus on accelerating CyPath Lung s
bioAffinity Technologies has announced strategic measures to cut $4 million in costs while accelerating sales growth for its noninvasive lung cancer test, CyPath Lung. These measures include significant workforce reductions and a focus on high-margin services. While the company expects these changes to optimize operations and profitability, they also anticipate a temporary decrease in revenue. The firm is committed to enhancing market presence, especially within federal healthcare systems, and aims to initiate a pivotal FDA trial for CyPath Lung in 2025.
Read more →BIAF▼ -9.6%on this news· ran to -43% by day 3
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million SAN ANTONIO, Texas (
bioAffinity Technologies, Inc. announced a warrant inducement that is expected to generate approximately $1.4 million in gross proceeds through the exercise of existing warrants. In exchange, investors will receive new warrants that may lead to the purchase of additional shares. The existing warrants' exercise price has been reduced to increase attractiveness. Furthermore, bioAffinity's CyPath Lung product has demonstrated promising results in lung cancer detection, highlighting the company's innovative approach to diagnostics.
Read more →BIAF▼ -11.1%on this news· ran to -37% by day 3shared move
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
bioAffinity Technologies has successfully closed a warrant inducement transaction, raising approximately $1.4 million. The company offered existing investors the opportunity to exercise outstanding warrants in exchange for new warrants at a reduced exercise price. This move is expected to bolster the company's financial position as it continues to develop its CyPath® Lung diagnostic technology.
Read more →BIAF▼ -16.7%on this news· ran to -36% by day 3shared move
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
bioAffinity Technologies announced a warrant inducement agreement to raise approximately $1.4 million through the exercise of existing warrants. In return, investors will receive new warrants to purchase additional shares at a reduced exercise price. The transaction is expected to close around February 26, 2025, subject to customary conditions.
Read more →BIAFbioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
bioAffinity Technologies announced the acceptance of its patent application for the CyPath® Lung diagnostic test, aimed at early-stage lung cancer detection. This patent, accepted by the Australian Patent Office, enhances the company's intellectual property portfolio. The test utilizes advanced flow cytometry and AI, demonstrating high sensitivity and accuracy in clinical studies. The patent is expected to be issued in three months unless challenged.
Read more →BIAF▼ -6.8%on this news
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung
bioAffinity Technologies has reported positive results from its CyPath® Lung pilot marketing program in Texas, with over 600 tests sold in 2024. The test demonstrates high sensitivity and specificity for early-stage lung cancer detection. The company plans to expand sales to Veteran and military medical systems in 2025, supported by its addition to the U.S. Federal Supply Schedule.
Read more →BIAF▼ -15.9%on this news
GOOD AFTERNOON - I AM EXCITED TO SPEAK WITH YOU TODAY AND DISCUSS OUR PLANS FOR 2025 AS WELL AS REVIEW THE SUCCESS BIOAFFINITY TECHNOLOGIES HAS ENJOYED THIS YEAR. DURING THIS PRESENTATION, CERTAIN FORWARD-LOOKING STATEME
BioAffinity Technologies is optimistic about its future as it discusses plans for 2025 and reviews a successful year in 2024. The company highlights impressive growth in sales of its lung cancer diagnostic test, CYPATH LUNG, which is showing high accuracy in detecting early-stage lung cancer. With ongoing expansion into federal healthcare programs and positive revenue projections, BioAffinity aims to increase its market presence and is focused on further development for additional lung disease diagnostics.
Read more →BIAF▲ +15.8%on this newsshared move
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
bioAffinity Technologies is hosting a live investor webinar on December 19, 2024, to discuss its noninvasive cancer detection product, CyPath® Lung. The CEO will highlight the product's benefits, including improved early-stage lung cancer diagnosis. The company recently secured a contract to make the test available to U.S. veterans, which is expected to boost sales.
Read more →BIAFbioAffinity Technologies Set for Continued Expansion in 2025
bioAffinity Technologies, Inc. has reported strong growth in sales of its CyPath® Lung test, projecting record revenues for 2025. The company anticipates a revenue increase of over 20% in 2024, driven by successful marketing initiatives and the integration of its subsidiary, Precision Pathology Laboratory Services. The CyPath® Lung test, known for its high accuracy in detecting lung cancer, is set to expand into strategic national markets.
Read more →BIAFVeterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
bioAffinity Technologies, Inc. announced that its product, CyPath® Lung, has been added to the Federal Supply Schedule, allowing it to be sold to VA healthcare facilities. This inclusion is expected to enhance lung cancer detection for veterans, who are at higher risk for the disease. The announcement was made during a presentation at the NAVREF meeting, highlighting the collaboration between bioAffinity and the Veterans Health Administration.
Read more →BIAFbioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
bioAffinity Technologies reported a revenue of $2.4 million for Q3 2024, marking a significant increase compared to the same period last year. The company saw a 75% rise in the number of physician offices offering its CyPath Lung test, which is now available in 11 states. Additionally, CyPath Lung has been added to the U.S. Federal Supply Schedule, improving access for veterans. Despite a net loss of $2.0 million, the company remains optimistic about future growth.
Read more →BIAFbioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 Expanded CyPath Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states Number of physician o
bioAffinity Technologies reported a revenue of $2.4 million for Q3 2024, a significant increase compared to the previous year. The company has expanded the reach of its CyPath Lung test, now receiving orders from 11 states, showing a 75% increase in participating physician offices. The test is now included in the U.S. Federal Supply Schedule, providing access to veterans at high risk for lung cancer. The company anticipates continued growth, forecasting $9.6 million in revenue for 2024.
Read more →BIAFSA Company Sets the Stage for Asian Expansion
BioAffinity Technologies Inc. has received a patent from the Japan Patent Office for its CyPath Lung test, marking a significant milestone for the company. This patent allows for the commercialization of its lung cancer detection technology in Asia, a market projected to reach nearly $900 million by 2028. Additionally, the company has been listed on the U.S. Federal Supply Schedule, enhancing its market presence.
Read more →BIAFbioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
bioAffinity Technologies has appointed Dr. William Bauta as the new Chief Science Officer following the retirement of Dr. Vivienne Rebel. Dr. Bauta, who has a strong background in research and development, is expected to lead advancements in the company's noninvasive lung cancer detection test, CyPath® Lung. His expertise is anticipated to enhance the company's product development and commercialization efforts.
Read more →BIAFbioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
bioAffinity Technologies has received a Japanese patent for its CyPath® Lung diagnostic test, which predicts lung cancer likelihood. This patent is a significant addition to its intellectual property portfolio, which includes multiple patents and pending applications. The company aims to improve lung cancer outcomes through earlier detection and is optimistic about future patents in other regions.
Read more →BIAF▼ -37%on this news
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
bioAffinity Technologies has announced a $2.66 million registered direct offering and concurrent private placement to institutional investors. The offering includes the sale of over 2 million shares at $1.30 each and warrants for additional shares. The funds will support the company's focus on noninvasive cancer detection technologies, particularly their CyPath® Lung test.
Read more →BIAF▼ -33.8%on this newsshared move
bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement SAN ANTONIO, TX (
bioAffinity Technologies has announced a $2.66 million securities purchase agreement with institutional investors for the direct offering of common stock and a concurrent private placement of warrants. The funding is intended to further their development of CyPath Lung, a noninvasive test that has shown high sensitivity and specificity in detecting early-stage lung cancer. The closing of the offering is expected around October 21, 2024, contingent on customary conditions, highlighting some associated risks. Meanwhile, the company emphasizes its commitment to addressing the urgent need for advanced cancer diagnostics.
Read more →BIAFbioAffinity Would Consider Inbound Approaches Among Funding Options – Execs
bioAffinity Technologies is considering inbound financing options as it expands nationally with its lung cancer screening product, CyPath Lung. The company has begun sales and plans to target federal markets. Analysts suggest that bioAffinity may attract interest from larger lab companies due to its innovative approach. The firm is also focused on developing additional tests for other respiratory conditions.
Read more →BIAF▲ +10.1%on this news· ran to -27% by day 3shared move
bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
bioAffinity Technologies' CyPath® Lung test is supported by newly published flow cytometry guidelines. The guidelines, co-authored by bioAffinity's VP, enhance the validation process for unique sample types like sputum. The test has demonstrated 92% sensitivity and 87% specificity in detecting lung cancer in patients with small nodules. This advancement aims to improve early detection and patient outcomes.
Read more →BIAFLung Cancer Test Fast-tracks San Antonio Firm’s Growth
bioAffinity Technologies Inc. has developed the CyPath Lung test, which utilizes AI to analyze phlegm samples for early detection of lung cancer. The test has gained rapid acceptance since its federal approval last year, leading to significant sales growth. A recent long-term federal contract will further expand its reach, particularly among veterans diagnosed with lung cancer.
Read more →BIAFSA Biomed to Expand Military Market Under New CFO
BioAffinity Technologies Inc. has successfully added its CyPath Lung test to the U.S. Federal Supply Schedule, allowing access for the Veterans Health Administration and Military Health System. This milestone is expected to significantly expand the company's market reach and revenue potential. The new CFO, J. Michael Edwards, will guide the company through this pivotal commercialization stage.
Read more →BIAFbioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
bioAffinity Technologies has appointed J. Michael Edwards as Chief Financial Officer, after he served as interim CFO. Edwards has a strong background in financial management and was instrumental in the company's IPO. He aims to leverage his experience to enhance the company's financial strategy and support the commercialization of their lung cancer detection product, CyPath® Lung.
Read more →BIAFbioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer Edwards rejoins the Company after serving as interim CFO SAN ANTONIO, TX (
bioAffinity Technologies, Inc. has appointed J. Michael Edwards as Chief Financial Officer, a role he previously held on an interim basis since September 15. Edwards has extensive experience in financial management and was instrumental in the company’s IPO in 2022. His leadership is expected to guide the financial strategies as the company commercializes its lung cancer detection test, CyPath Lung, which has shown promising clinical results. This move signifies the company's commitment to advancing its innovative cancer detection technology.
Read more →BIAF▲ +13.7%on this newsshared move
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
bioAffinity Technologies announced that its CyPath® Lung test will be added to the U.S. Federal Supply Schedule, allowing Veterans and federal health services access to this noninvasive lung cancer diagnostic. The test aims to improve early detection and potentially save millions in healthcare costs. The initiative is particularly significant given the high lung cancer risk among veterans.
Read more →BIAF▲ +13.7%on this newsshared move
bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath Lung Test Noninvasive diagnostic test for lung cancer available to U.S. Veterans, other federal health services patients SAN ANTONIO, TX (
bioAffinity Technologies has been awarded a U.S. Federal Supply Schedule contract to include its noninvasive CyPath Lung test for early-stage lung cancer detection. This contract facilitates access for the Veterans Health Administration and Military Health System, benefiting millions of Veterans at high risk of lung cancer. CyPath Lung demonstrates high diagnostic accuracy and could significantly reduce healthcare costs associated with lung cancer follow-ups. The approval is a critical step in improving health outcomes for Veterans, who disproportionately suffer from lung cancer.
Read more →BIAFPeer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
A peer-reviewed study indicates that bioAffinity Technologies' CyPath® Lung test could save an average of $2,773 per Medicare patient and $6,460 per private-payer patient by reducing unnecessary follow-ups and complications in lung cancer diagnosis. The study highlights the test's high sensitivity and specificity, suggesting it could significantly improve early lung cancer detection and healthcare costs.
Read more →BIAFbioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
bioAffinity Technologies announced the resignation of CFO Michael Dougherty, who is leaving for a new opportunity in the energy sector. Michael Edwards, the former CFO, will step in as interim CFO until a permanent replacement is found. The company anticipates a smooth transition due to established financial processes and a strong team.
Read more →BIAFbioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO Edwards held CFO position at bioAffinity for nine years, leading Company through successful IPO SAN ANTONIO, TX (
bioAffinity Technologies, Inc. announced the resignation of its CFO, Michael Dougherty, who is leaving for a new opportunity in the energy sector. Michael Edwards, who previously held the CFO position and oversaw the company's IPO, will return as interim CFO. The company expects a seamless transition, aided by the solid financial processes Dougherty implemented during his tenure, which involved significant acquisitions and advancements in their noninvasive cancer detection technology, CyPath Lung. The search for a permanent CFO will begin immediately.
Read more →BIAFbioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing CyPath® Lung Sales
bioAffinity Technologies reported a revenue of $2.4 million for Q2 2024, driven by a significant increase in sales of its CyPath® Lung test, which rose 217% from the previous quarter. The company has expanded its market reach to eight states and raised its sales forecast for the year by 85%. Despite these positive developments, bioAffinity reported a net loss of $2.1 million and a decrease in cash reserves.
Read more →BIAF▼ -27.3%on this news
bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million SAN ANTONIO, Texas (
bioAffinity Technologies, Inc. announced the pricing of a registered direct offering and a concurrent private placement totaling $1.75 million. This includes the exercise of existing warrants and issuance of new warrants to investors, scheduled for August 5, 2024. The company aims to enhance funding for its innovative lung cancer detection system, CyPath Lung, which has demonstrated impressive results in clinical trials. The offerings are contingent on stockholder approvals, adhering to SEC regulations.
Read more →BIAF▲ +7.2%on this news
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath® Lung
bioAffinity Technologies reported a remarkable 217% increase in sales of its CyPath® Lung test in the second quarter of 2024 compared to the first quarter. The company has raised its full-year sales forecast by 85%, driven by an expanding customer base among pulmonology practices. CyPath® Lung is a noninvasive test for early lung cancer detection, showing high sensitivity and specificity. The company plans a broader market launch in the fourth quarter of 2024.
Read more →BIAF▲ +7.2%on this newsshared move
bioAffinity Technologies Reports 217% Sales Growth in Second Quarter 2024 for CyPath Lung Sales of CyPath Lung tests continue to accelerate as sales team expands customer base of pulmonology practices SAN ANTONIO, TX (
bioAffinity Technologies reported an impressive 217% growth in sales of its CyPath Lung test in the second quarter of 2024 compared to the first quarter. The company has raised its full-year sales forecast for CyPath Lung by 85%, indicating strong market demand and effective marketing strategies, particularly in Texas. This noninvasive test for early-stage lung cancer is gaining traction among pulmonologists and is seen as a valuable diagnostic tool due to its high sensitivity and specificity rates. The company anticipates expanding its market outreach further as sales team efforts continue to grow.
Read more →BIAFbioAffinity Technologies News Update
bioAffinity Technologies, Inc. has reported a substantial increase in the adoption of its noninvasive diagnostic test, CyPath® Lung, for early lung cancer detection. CEO Maria Zannes will appear on Bloomberg TV to discuss the company's advancements. The test has seen 139% growth in adoption since January 2024, expanding to multiple states beyond Texas.
Read more →BIAFbioAffinity Technologies Reports Accelerating Growth of Physician Practices Ordering CyPath® Lung Tests
bioAffinity Technologies, Inc. reported significant growth in the adoption of its CyPath® Lung tests, with a 139% increase in pulmonology practices since January 2024. The sales performance has surpassed initial targets, leading to an expansion into eight states beyond Texas. The company attributes this success to effective marketing and positive word-of-mouth among physicians. CyPath® Lung is designed to improve early detection of lung cancer using noninvasive methods.
Read more →BIAFbioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes
bioAffinity Technologies reported a record revenue of $2.4 million for Q1 2024, driven by a significant increase in orders for its CyPath® Lung test, which saw a 547% annualized growth rate. The company has raised its revenue forecast for 2024 by 35% due to expanding adoption and Medicare reimbursement. Despite a net loss of $2.1 million, the company is optimistic about its growth trajectory in the lung cancer detection market.
Read more →BIAFbioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath Lung Sales and Increased Laboratory Volumes Expanded, experienced sales team more than doubles number of physician p
bioAffinity Technologies reported a record Q1 revenue of $2.4 million for 2024, driven by significant growth in sales of its CyPath Lung test. The company has doubled its physician orders and adjusted its revenue forecast upward by 35% due to a robust increase in demand. Medicare reimbursement for CyPath Lung became available in January 2024, which is expected to support further adoption of the test. Despite this growth, bioAffinity posted a net loss of $2.1 million, reflecting ongoing investments in product development and market expansion.
Read more →BIAF▼ -5.4%on this news
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
bioAffinity Technologies has appointed Dr. David Elzi as Vice President of Product Development to enhance its diagnostic offerings, particularly focusing on lung cancer detection. The company is developing two new tests utilizing flow cytometry and AI, in collaboration with the Department of Defense's largest military health organization. These initiatives aim to improve early detection of lung diseases, including COPD.
Read more →BIAFbioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
bioAffinity Technologies has expanded its partnership with the American Cancer Society to enhance lung cancer screening efforts across the U.S. The initiative aims to raise awareness and funding for lung cancer screening, emphasizing the importance of early detection. Their product, CyPath® Lung, is highlighted for its effectiveness in identifying lung cancer in high-risk patients.
Read more →BIAFbioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
bioAffinity Technologies reported a substantial increase in revenue for fiscal year 2023, reaching $2.5 million, up from just $5,000 in 2022. This growth was driven by the acquisition of Precision Pathology Laboratory Services and increased sales of their CyPath® Lung test. The company also achieved a key milestone with CMS's payment determination for the test in 2024, supporting its commercialization strategy. Despite a net loss of $7.9 million, the company remains optimistic about its future prospects.
Read more →BIAFbioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results SAN ANTONIO, Texas (
bioAffinity Technologies reported its financial results for Q4 and FY 2023, showcasing a remarkable revenue increase to $2.5 million, spurred by the acquisition of Precision Pathology Laboratory Services and strong sales of its CyPath Lung test. The company achieved a 350% growth in orders of CyPath Lung tests in early 2024 compared to late 2023 and secured payment approval from CMS for the next calendar year. However, it also reported a net loss of $7.9 million for the year, up from $8.1 million in the previous year, alongside rising administrative expenses. Overall, the company is well-positioned for future growth in the early detection of lung cancer.
Read more →BIAFbioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
bioAffinity Technologies has successfully closed a $2.5 million registered direct offering and concurrent private placement. The offering involved the sale of 1,600,000 shares of common stock at a price of $1.5625 per share. The company plans to use the proceeds for working capital and general corporate purposes.
Read more →BIAF▼ -50%on this newsshared move
bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement SAN ANTONIO, Texas (
bioAffinity Technologies, Inc. has announced a successful pricing of a $2.5 million registered direct offering along with a concurrent private placement. This deal involves the sale of 1,600,000 shares of common stock at a price of $1.5625 per share, alongside common warrants allowing for future share purchases. Closing of the offering is anticipated by March 8, 2024, subject to customary conditions. The raised funds are aimed at supporting the company's cancer diagnostic initiatives, particularly focusing on their CyPath Lung product, which has demonstrated significant accuracy in early lung cancer detection.
Read more →BIAF▲ +27.7%on this newsshared move
bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung
bioAffinity Technologies reported a remarkable 375% increase in orders for its CyPath® Lung test over the past three months. The growth is attributed to heightened physician interest, a new reimbursement code, and an expanded sales force. The company is on track to meet its sales forecast and aims to expand nationally, reflecting confidence in the lung cancer diagnostics market.
Read more →BIAF▲ +27.7%on this newsshared move
bioAffinity Technologies Reports Accelerating Sales Growth of CyPath Lung Increasing physician interest, newly approved reimbursement code driving growth SAN ANTONIO (
bioAffinity Technologies, Inc. reported a significant 375% increase in sales of its CyPath Lung tests over the past three months compared to the prior period. This growth is attributed to heightened physician interest driven by a newly approved reimbursement code and the completion of their branding and sales expansion efforts. The company is on track to meet its sales forecast for the limited test market launch in Texas, with plans to expand nationally following successful results. CyPath Lung shows strong clinical performance with high sensitivity, specificity, and accuracy in detecting early-stage lung cancer, enhancing the potential for improved patient outcomes.
Read more →BIAFMedical Director of Pennsylvania’s Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice
bioAffinity Technologies announced that Dr. Sandeep Bansal has joined its Medical and Scientific Advisory Board. Dr. Bansal will incorporate the CyPath® Lung test into his practice, which aids in the early detection of lung cancer. The test has demonstrated high sensitivity and specificity in clinical studies, supporting bioAffinity's mission to improve lung health.
Read more →BIAFbioAffinity Technologies In the News
bioAffinity Technologies has recently achieved significant milestones, including passing CAP accreditation for its laboratory services and receiving a patent in India for targeted cancer treatments. The company also highlighted its collaboration with ScienceSoft to enhance its CyPath® Lung diagnostic system. CEO Maria Zannes emphasized the importance of noninvasive testing for early lung cancer detection during a recent investment webinar.
Read more →BIAFbioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer
bioAffinity Technologies has received a patent from the Indian Patent Office for its innovative cancer treatment methods using porphyrin compounds. This patent strengthens the company's position in the market and supports its ongoing research in targeted therapies for lung cancer. The company aims to enhance patient outcomes through its noninvasive diagnostic test, CyPath® Lung.
Read more →BIAFbioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
bioAffinity Technologies has appointed Dr. Jamie Platt to its Board of Directors, effective December 1, 2023. Dr. Platt brings over two decades of experience in diagnostics and has a proven track record in leading successful M&A transactions. Her expertise is expected to enhance the commercialization of the company's noninvasive lung cancer test, CyPath® Lung.
Read more →BIAFbioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors SAN ANTONIO, Texas (
bioAffinity Technologies, Inc. announced the appointment of Dr. Jamie Platt to its Board of Directors, effective December 1, 2023. Dr. Platt, with two decades of experience in diagnostics, is expected to enhance the company's growth, particularly in commercializing CyPath Lung, a noninvasive test for early lung cancer detection. She has a successful history of transforming research entities into commercial successes, including recent notable M&A activities. Dr. Platt replaces Mohsin Y. Meghji, who resigned for personal reasons without disputes. The announcement highlights the potential impact of CyPath Lung in improving early cancer detection outcomes.
Read more →BIAF▲ +23%on this newsshared move
CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024
bioAffinity Technologies announced that the Centers for Medicare and Medicaid Services (CMS) has finalized the payment determination for its noninvasive test, CyPath® Lung, effective January 1, 2024. This inclusion in the 2024 clinical laboratory fee schedule is expected to facilitate reimbursement and increase the test's appeal to physicians and patients. The test has shown promising clinical trial results with high sensitivity and specificity for early-stage lung cancer detection.
Read more →BIAF▲ +23%on this newsshared move
CMS Posts Final Payment Determination for bioAffinity Technologies' CyPath Lung Effective January 2024 SAN ANTONIO, Texas (
bioAffinity Technologies has announced that the Centers for Medicare and Medicaid Services (CMS) has finalized its payment determination for CyPath Lung, effective January 2024. This noninvasive test is now included in CMS' 2024 clinical laboratory fee schedule, which aids in reimbursement by Medicare and private payers. The test demonstrated robust effectiveness in clinical trials, showing 92% sensitivity and 88% accuracy in detecting early-stage lung cancer, which may enhance its adoption among at-risk patients and healthcare providers.
Read more →BIAFbioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
bioAffinity Technologies announced that David Elzi, Ph.D., has joined the Membership Committee of the American Society for Cell Biology. His role will focus on enhancing member engagement and promoting the importance of cell biology. Elzi will also host a roundtable at Cell Bio 2023 to assist scientists transitioning to the biotech industry.
Read more →BIAFbioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening
bioAffinity Technologies has partnered with the American Cancer Society to launch 'The Power of Three' campaign aimed at increasing lung cancer screening in Texas. The initiative supports local programs and promotes bioAffinity's CyPath® Lung test, which has demonstrated high accuracy in early lung cancer detection. The campaign seeks to improve screening rates significantly, addressing a critical health issue.
Read more →BIAFbioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update SAN ANTONIO (
bioAffinity Technologies reported its third quarter 2023 financial results and business updates, highlighting a successful acquisition of Village Oaks Pathology Services and a preliminary favorable CMS payment decision for its CyPath Lung test. The company anticipates the acquisition will generate revenue of approximately $8.7 million over the next year, while also projecting growth in sales through expanded marketing efforts. Although the net loss for the quarter was reduced, cash reserves saw a notable decline, signaling the need for potential capital raising in favorable market conditions.
Read more →BIAF▲ +6.5%on this news
SA Biotech Hire to Bolster National Expansion
bioAffinity Technologies has appointed Dallas Coleman as national sales director to enhance the commercialization of its CyPath Lung cancer detection technology. With over 15 years of experience in medical sales, Coleman aims to fine-tune the company's market strategy and leverage his relationships to boost awareness among physicians. This hiring follows the company's recent achievement of securing reimbursement approval, which is anticipated to expand market opportunities.
Read more →BIAFbioAffinity Technologies Names Dallas J. Coleman as National Director of Sales
bioAffinity Technologies has appointed Dallas J. Coleman as the National Director of Sales. With over 15 years of experience in medical sales, Coleman will lead the CyPath® Lung sales team and focus on expanding the commercialization of this noninvasive lung cancer detection test. His expertise is expected to enhance the company's market launch efforts across Texas and nationally.
Read more →BIAFbioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference
bioAffinity Technologies, Inc. will participate in the 8th Annual Dawson James Small Cap Growth Conference, where CEO Maria Zannes will present a corporate update and engage in one-on-one meetings with investors. The company recently acquired Precision Pathology Laboratory, enhancing its capabilities for the CyPath® Lung test, which is aimed at early-stage lung cancer detection. Zannes expressed optimism about the company's commercial growth strategy based on positive market research.
Read more →BIAF▲ +5.5%on this news· ran to +30% by day 3
bioAffinity Aims to Make Lung Cancer Test Available Nationally Following Pathology Lab Acquisition
bioAffinity is expanding its sputum-based lung cancer test, CyPath Lung, through the acquisition of Precision Pathology Services. This acquisition allows for full control over the test's development and marketing, with plans for a national launch in 2024. The test has shown strong performance in trials, particularly for early detection of lung cancer. bioAffinity aims to leverage its new capabilities to enhance its testing pipeline and improve patient outcomes.
Read more →BIAFVILLAGE OAKS PATHOLOGY SERIVCES, P.A. D/B/A PRECISION PATHOLOGY SERVICES FINANCIAL STATEMENTS For the years ended
The financial statements for Village Oaks Pathology Services, P.A. reveal significant changes from 2021 to 2022. While net revenue has increased, the company reported substantial losses, raising doubts about its ability to continue as a going concern. An independent auditor's report confirms compliance with GAAP but notes potential financial instability due to negative cash flows and higher operating expenses. The company needs to address these concerns moving forward.
Read more →BIAFbioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services
bioAffinity Technologies has acquired the laboratory assets of Precision Pathology Services to enhance its CyPath® Lung test for early-stage lung cancer detection. The acquisition, valued at $3.5 million, aims to build a commercial laboratory that supports the upcoming FDA pivotal trial. Dr. Roby Joyce, founder of Precision Pathology, will join bioAffinity's board, bringing extensive experience in pathology.
Read more →BIAFbioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference
bioAffinity Technologies, Inc. will participate in the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023. CEO Maria Zannes is set to present a corporate update and meet with institutional investors. The company focuses on noninvasive lung cancer detection and has developed the CyPath® Lung test, which has demonstrated high sensitivity and specificity.
Read more →BIAFbioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update SAN ANTONIO (
bioAffinity Technologies reported its financial results for Q2 2023 and provided a business update, revealing important developments for its CyPath Lung product. Highlights include the issuance of a CPT code by the AMA, which is expected to facilitate reimbursement processes. The company also initiated a pilot marketing program in Texas and noted sales to the Department of Defense for its lung cancer diagnostic tests. Despite reporting increased revenues, bioAffinity recorded a net loss for the quarter, largely due to rising operational expenses.
Read more →BIAFbioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update
bioAffinity Technologies reported its financial results for Q2 2023, highlighting a significant increase in revenue compared to the prior year. The company received a CPT code for its CyPath® Lung test, enhancing its market potential. Additionally, the Department of Defense purchased tests for research purposes. However, the company also reported a larger net loss and rising expenses.
Read more →BIAFAMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung Cancer
bioAffinity Technologies announced that the AMA has issued a CPT code for its CyPath® Lung test, effective October 1, 2023. This noninvasive test aims to improve early-stage lung cancer detection, showing promising clinical trial results. The CPT code will aid in reimbursement processes, making the test more accessible to patients at high risk for lung cancer.
Read more →BIAFbioAffinity Technologies Reports First Quarter 2023 Financial Results SAN ANTONIO, Texas (
bioAffinity Technologies reported its financial results for the first quarter of 2023, showcasing the launch of CyPath Lung, a noninvasive test for early-stage lung cancer. The company appointed a new CFO, Michael Dougherty, to strengthen its financial strategy. Despite generating initial revenues, bioAffinity experienced a net loss of $1.5 million and an increase in operating expenses compared to the previous year. The clinical validation study for CyPath Lung demonstrated promising results, generating optimism about its commercialization.
Read more →BIAF▲ +5.1%on this news
bioAffinity Technologies Names Michael Dougherty as Chief Financial Officer SAN ANTONIO, Texas (
bioAffinity Technologies has appointed Michael Dougherty as its new Chief Financial Officer, effective May 1, 2023. Dougherty brings over 20 years of financial management experience, having held significant roles at major firms, including Amazon. His expertise is anticipated to be critical in supporting the nationwide rollout of CyPath Lung, the company's noninvasive test for early-stage lung cancer, as well as in expanding the company's brand and pursuing therapeutic opportunities. Former CFO Michael Edwards will assist during the transition.
Read more →BIAFbioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium SAN ANTONIO, Texas (
bioAffinity Technologies, Inc. will present at the Cleveland Clinic's Advances in Early Lung Cancer Detection symposium on April 27, 2023. The presentation, led by Executive Vice President Vivienne I. Rebel, MD, PhD, will highlight the company's CyPath Lung test, which is designed for noninvasive detection of early-stage lung cancer. This symposium is pivotal as it brings together leaders in lung cancer research to promote innovative detection methods.
Read more →BIAF▲ +7.8%on this news
bioAffinity Technologies to Ring Nasdaq Closing Bell Today SAN ANTONIO, Texas (
bioAffinity Technologies, Inc. (Nasdaq: BIAF) is set to ring the Nasdaq closing bell today to commemorate its 2022 initial public offering. CEO Maria Zannes highlighted the occasion as a celebration of the company's milestones and the launch of its first commercial product, CyPath Lung, which offers a noninvasive method to detect early-stage lung cancer. The ceremony takes place from 3:45 to 4:05 p.m. Eastern time and will be streamed live on Nasdaq's platforms.
Read more →BIAF▼ -13.2%on this newsshared move
bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results Conference Call Scheduled for
bioAffinity Technologies reported its financial results for Q4 and the full year 2022, highlighting significant capital raises totaling approximately $13.8 million. The company achieved promising results in its clinical validation trial for CyPath Lung, which generated $2,500 in revenue during Q4. Despite these positive developments, bioAffinity recorded a net loss of $8.2 million for the year. The company is managing a pivotal trial to seek FDA clearance and is expanding its diagnostic capabilities to include additional lung diseases.
Read more →BIAFbioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath Lung for Noninvasive Detection of Early-Stage Lung Cancer SAN ANTONIO, Texas (
bioAffinity Technologies has announced the publication of a peer-reviewed paper in the Journal of Visualized Experiments regarding their proprietary porphyrin-modified beads, which improve the accuracy and efficiency of their CyPath Lung test for early-stage lung cancer detection. This test utilizes advanced techniques, including automated flow cytometry and artificial intelligence, achieving high rates of sensitivity and specificity in clinical trials. The recognition through peer review underscores the company's dedication to advancing lung cancer diagnostics, aligning with their mission to enhance survivability through early detection.
Read more →BIAFbioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on
bioAffinity Technologies, Inc. announced it will report its financial results for the fourth quarter of 2022 on March 31, 2023, followed by a conference call on April 3, 2023. The company focuses on non-invasive diagnostic tests for early-stage cancer and lung diseases, with its CyPath Lung product showing promising results in detection. The conference call will allow stakeholders to discuss these results and ask questions.
Read more →BIAFbioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications Company enlists Havas Health & You, Trinity Life Sciences to help build CyPath Lung brand
bioAffinity Technologies, Inc. has appointed Julie Anne Overton as its new Director of Corporate Communications, a move intended to bolster the communication strategy around its CyPath Lung brand. The company has also enlisted the expertise of marketing firms Havas Health & You and Trinity Life Sciences to enhance its branding and commercialization efforts for CyPath Lung, a non-invasive test for early-stage lung cancer detection. CyPath Lung has demonstrated strong clinical trial results, indicating its potential as an effective diagnostic tool in oncology.
Read more →BIAF▲ +75.5%on this news
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research Noninvasive Test Developed Using Machine Learning Detects Early
bioAffinity Technologies announced the publication of results from its clinical trial demonstrating that CyPath Lung, a non-invasive diagnostic test, can accurately detect early-stage lung cancer in high-risk patients. The test achieved an impressive sensitivity of 92% and specificity of 87%, positioning it as a reliable alternative to invasive diagnostic procedures. This publication in the peer-reviewed journal Respiratory Research supports the ongoing development of CyPath Lung as a valuable tool for lung cancer screening and patient care.
Read more →BIAF▲ +5.8%on this news
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
bioAffinity Technologies announced that the U.S. Patent and Trademark Office has granted a Notice of Allowance for its patent application concerning novel compounds designed for targeted cancer treatment delivery. These porphyrin-based compounds are expected to enhance the effectiveness of chemotherapy while reducing side effects. The patent, which will be granted to their subsidiary OncoSelect, provides protection until 2037 and reflects bioAffinity's commitment to developing innovative therapies to improve patient outcomes in cancer care.
Read more →BIAFbioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench
Technologies Expands Diagnostic Division with Promotions New Hires to Strengthen Clinical Bench ANTONIO, TX - Dec. 15, 2022 - bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and d
Read more →BIAFbioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting bioAffinity reports on a potential therapeutic approach that kills cancer cells with
Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting reports on a potential therapeutic approach that kills cancer cells without harm to normal cells ANTONIO, TX - Dec. 1, 2022 - bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotec
Read more →BIAF▲ +7.3%on this news· ran to +19% by day 1
bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company's Scientific and Medical Advisory Board
bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company's Scientific and Medical Advisory Board SAN ANTONIO, TX - Nov. 10, 2022 -- bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced Sheila Habib, MD, Director of Pulmonary Lung Nodule
Read more →BIAFbioAffinity Technologies to Report Third Quarter 2022 Financial Results San Antonio, TX
Technologies to Report Third Quarter 2022 Antonio, TX - Nov. 8, 2022 - bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced that the Company will host a conference call and audio webcast on Monday, Nov. 14, 2022, at 8 a.m. ET to discuss its corporate and financi
Read more →BIAFbioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia Awarded patents protect novel porphyrin conjugated compounds for selective delivery of can
Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia patents protect novel porphyrin conjugated compounds for selective delivery of cancer treatments ANTONIO, TX - Oct. 25, 2022 - bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced the P
Read more →BIAFbioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference Powerful platform reveals the lung environment for diagnosing lung diseases
bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference Powerful platform reveals the lung environment for diagnosing lung diseases SAN ANTONIO, TX - Oct. 12, 2022 - bioAffinity Technologies, Inc., (NASDAQ: BIAF; BIAFW) will pre
Read more →BIAF▲ +37.7%on this news
bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M
bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M SAN ANTONIO, TX - September 28, 2022 - bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt o
Read more →BIAFbioAffinity Technologies Announces Pricing of IPO San Antonio, TX
Technologies Announces Pricing of IPO Antonio, TX - Sept. 1, 2022 - bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, a
Read more →Competitive Position
How BIAF ranks across every disease it competes inCompetitive Position is a premium feature
See how BIAF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial